Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model
出版年份 2023 全文链接
标题
Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model
作者
关键词
-
出版物
Multiple Sclerosis and Related Disorders
Volume -, Issue -, Pages 105100
出版商
Elsevier BV
发表日期
2023-10-22
DOI
10.1016/j.msard.2023.105100
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis
- (2023) Imtiaz A Samjoo et al. Journal of Comparative Effectiveness Research
- The Economic Burden of Multiple Sclerosis in the United States
- (2022) Bruce Bebo et al. NEUROLOGY
- Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives
- (2022) Gary Álvarez Bravo et al. Cells
- Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study
- (2021) Ludwig Kappos et al. JAMA Neurology
- Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis
- (2021) Zhuoyi Liu et al. AUTOIMMUNITY REVIEWS
- Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions
- (2021) Marisa P McGinley et al. LANCET
- Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis
- (2021) Simone Huygens et al. VALUE IN HEALTH
- Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis
- (2021) Matthijs M. Versteegh et al. VALUE IN HEALTH
- Exploiting relationships between outcomes in Bayesian multivariate network meta‐analysis with an application to relapsing‐remitting multiple sclerosis
- (2020) Ed Waddingham et al. STATISTICS IN MEDICINE
- Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis
- (2020) Imtiaz A Samjoo et al. Journal of Comparative Effectiveness Research
- Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis
- (2019) Huihui Li et al. JOURNAL OF NEUROLOGY
- Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis
- (2019) Rachael McCool et al. Multiple Sclerosis and Related Disorders
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
- (2019) Jeffrey A Cohen et al. LANCET NEUROLOGY
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
- (2019) Giancarlo Comi et al. LANCET NEUROLOGY
- EDSS progression assessment heterogeneity in MS according to geographical areas
- (2018) F. Bovis et al. ANNALS OF NEUROLOGY
- New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands
- (2017) Bernard Uitdehaag et al. Multiple Sclerosis Journal
- New insights into the burden and costs of multiple sclerosis in Europe
- (2017) Gisela Kobelt et al. Multiple Sclerosis Journal
- New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands
- (2017) Bernard Uitdehaag et al. Multiple Sclerosis Journal
- New insights into the burden and costs of multiple sclerosis in Europe
- (2017) Gisela Kobelt et al. Multiple Sclerosis Journal
- Affordability of medicines in the European Union
- (2017) Tomasz Zaprutko et al. PLoS One
- Cost–utility analysis comparing radioactive iodine, anti-thyroid drugs and total thyroidectomy for primary treatment of Graves’ disease
- (2016) Peter J Donovan et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
- (2016) Fred Lublin et al. LANCET
- Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment
- (2016) Stacy Ellen Hatcher et al. JAMA Neurology
- Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide
- (2014) Emanuela Colombo et al. ANNALS OF NEUROLOGY
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis
- (2013) Omar Khan et al. ANNALS OF NEUROLOGY
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now